Modulatory effects of bortezomib on host immune cell functions.

Abstract:

:Bortezomib is an inhibitor of the ubiquitin-proteasome proteolytic pathway responsible for intracellular protein turnover. Cellular proteins controlled by this pathway represent a diverse group of potential therapeutic targets, particularly in cancer cells, which exploit this proteasomal pathway to promote their growth and diminish apoptosis. Along with inhibiting the proteasome and thus sensitizing tumor cells to apoptosis, bortezomib may also have multiple effects on the host immune responses. This review summarizes the effects that bortezomib may play on immune cell subsets in various disease states in modifying lymphocyte receptors, ligands, the expression of various cytokines and chemokines and their downstream signaling. We also propose steps that can be taken to refine combinatorial strategies that include bortezomib to improve current immunotherapeutic approaches.

journal_name

Immunotherapy

journal_title

Immunotherapy

authors

Pellom ST Jr,Dudimah DF,Thounaojam MC,Sayers TJ,Shanker A

doi

10.2217/imt.15.66

subject

Has Abstract

pub_date

2015-01-01 00:00:00

pages

1011-22

issue

9

eissn

1750-743X

issn

1750-7448

journal_volume

7

pub_type

杂志文章,评审
  • First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland.

    abstract::Aim: To evaluate treatment results in advanced/metastatic melanoma patients treated with anti-PD-1 immunotherapy in routine practice in oncology centers in Poland. Methods: Multicenter retrospective analysis included 499 patients with unresectable/metastatic (stage IIIC-IV) melanoma treated with anti-PD-1 in first-lin...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0217

    authors: Cybulska-Stopa B,Pacholczak-Madej R,Kamińska-Winciorek G,Ziętek M,Czarnecka AM,Piejko K,Galus Ł,Ziółkowska B,Kieszko S,Kempa-Kamińska N,Calik J,Rolski J,Sałek-Zań A,Gajewska-Wicher K,Drosik-Kwaśniewska A,Rogala P,Kubiatow

    更新日期:2021-03-01 00:00:00

  • Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential.

    abstract::HER2/neu is expressed in the majority of in situ breast cancers, but maintained in 20-30% of invasive breast cancer (IBC). During breast tumorigenesis, there is a progressive loss of anti-HER2 CD4(pos) Th1 (anti-HER2Th1) from benign to ductal carcinoma in situ, with almost complete loss in IBC. This anti-HER2Th1 respo...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2016-0052

    authors: De La Cruz LM,Nocera NF,Czerniecki BJ

    更新日期:2016-10-01 00:00:00

  • FOCIS goes south: advances in translational and clinical immunology.

    abstract::FOCIS goes South: Advances in Translational and Clinical Immunology was the first Federation of Clinical Immunology Societies (FOCIS) ( www.focisnet.org ) meeting held in Latin America (May 15-17, 2017, Santiago de Chile, Chile). The meeting was organized as a 3-day workshop and was fostered by the Millennium Institut...

    journal_title:Immunotherapy

    pub_type:

    doi:10.2217/imt-2017-0079

    authors: Kalergis AM,Anegon I,González PA

    更新日期:2017-09-01 00:00:00

  • Designing two-in-one antibodies.

    abstract::Evaluation of: Bostrom J, Shang-Fan Y, Kan D et al.: Variants of the antibody Herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323, 1610-1614 (2009). The longstanding held notion that one antibody equals one antigen and, hence, one function has been challenged in recent years. Improved t...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.09.39

    authors: Valladares IG,Espinoza LR

    更新日期:2009-09-01 00:00:00

  • CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy.

    abstract::Following cancer treatment, patients often report behavioral and cognitive changes. Novel cancer immunotherapeutics have the potential to produce sustained cancer survivorship, meaning patients will live longer with the side effects of treatment. Given the role of inflammatory pathways in mediating behavioral and cogn...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2017-0056

    authors: McGinnis GJ,Raber J

    更新日期:2017-09-01 00:00:00

  • Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients.

    abstract::Background: Severe pneumonia and acute respiratory distress syndrome (ARDS) due to COVID-19 is a challenge for nowadays medical practice. Although there is no clarity in the principal mechanism of lung damage and ARDS development, it has been suggested that one of the main reasons of this pathology is the hyperactivat...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0154

    authors: Cala-García JD,Sierra-Bretón JD,Cavelier-Baiz JE,Faccini-Martínez ÁA,Pérez-Díaz CE

    更新日期:2020-10-01 00:00:00

  • A case of fulminant Type 1 diabetes following anti-PD1 immunotherapy in a genetically susceptible patient.

    abstract::Programmed cell death-1 protein (PD-1) is an immune checkpoint that has gained popularity in the treatment of several advanced cancers. Inhibiting this checkpoint is known to enhance immune response, but is also known to diminish immune tolerance and to increase autoimmune toxicity. We discuss a case of rapid onset fu...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2017-0020

    authors: Araújo M,Ligeiro D,Costa L,Marques F,Trindade H,Correia JM,Fonseca C

    更新日期:2017-06-01 00:00:00

  • An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases.

    abstract::In COVID-19, the inflammatory cytokine-release syndrome is associated with the progression of the disease. Itolizumab is a monoclonal antibody that recognizes human CD6 expressed in activated T cells. The antibody has shown to be safe and efficacious in the treatment of moderate to severe psoriasis. Its effect is asso...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0235

    authors: Filgueira LM,Cervantes JB,Lovelle OA,Herrera C,Figueredo C,Caballero JA,Sánchez N,Berrio J,Lorenzo G,Cepeda M,Ramos M,Saavedra D,Añe-Kouri AL,Mazorra Z,Leon K,Crombet T,Caballero A

    更新日期:2021-03-01 00:00:00

  • Remarkable response to combined immunochemotherapy in patients with metastatic triple-negative breast cancer.

    abstract::Background: Progress in immunotherapy (IT) has shifted treatment paradigms for multiple malignancies. In March 2019, the combination of nab-paclitaxel and atezolizumab was approved by the US FDA for patients with PD-L1 positive metastatic triple-negative breast cancer based on positive results of the Impassion130 tria...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0202

    authors: Philipovskiy A,Chambers K,Konstantinidis I,McCallum R,Corral J,Gaur S

    更新日期:2020-12-01 00:00:00

  • Novel immunotherapeutic strategies for pyelonephritis.

    abstract::Acute pyelonephritis is an infection of the renal parenchyma and renal pelvis. When it is caused by a typical pathogen in an immunocompetent female patient with normal urinary tract, it is considered uncomplicated. In all other cases, sepsis is the most worrisome complication. In the event of sepsis, patients should b...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.15.98

    authors: Tsaganos T,Giamarellos-Bourboulis EJ

    更新日期:2016-01-01 00:00:00

  • Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises.

    abstract::Over the last two decades, anti-CD20 monoclonal antibody (mAb) therapy has improved patient outcome in B-cell malignancies, and confirmed CD20 as an important target in chronic lymphocytic leukemia (CLL). Until recently, the gold standard was based on the utilization of rituximab combined with chemotherapy (fludarabin...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2015-0015

    authors: Bagacean C,Zdrenghea M,Tempescul A,Cristea V,Renaudineau Y

    更新日期:2016-05-01 00:00:00

  • Targeting CD4(+) T cells for the treatment of sarcoidosis: a promising strategy?

    abstract::Sarcoidois is an inflammatory disease of unknown origin characterized by the abnormal accumulation of noncaseating granulomas at sites of disease activity in multiple organs throughout the body with a predilection for the lungs. Because the exact trigger that leads to disease activity is still under investigation, cur...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.103

    authors: Celada LJ,Drake WP

    更新日期:2015-01-01 00:00:00

  • Nivolumab plus ipilimumab for soft tissue sarcoma: a single institution retrospective review.

    abstract::Aim: To analyze the efficacy of checkpoint inhibitors in soft tissue sarcoma. Materials & methods: We retrospectively reviewed patients with advanced soft tissue sarcoma treated with ipilimumab and nivolumab. All patients who received at least one cycle were included. Results: One patient had a complete response and f...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0155

    authors: Zhou M,Bui N,Bolleddu S,Lohman M,Becker HC,Ganjoo K

    更新日期:2020-12-01 00:00:00

  • Use of a multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) for bacterial meningitis prevention.

    abstract::Developing effective vaccines against Neisseria meningitidis serogroup B has been challenging for several reasons, including the fact that the capsular polysaccharide of N. meningitidis serogroup B is a poor antigen. Therefore, studies have focused on developing vaccines that target capsular protein meningococcal anti...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.11

    authors: Esposito S,Castellazzi L,Bosco A,Musio A,Stoddard J

    更新日期:2014-01-01 00:00:00

  • Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects.

    abstract::Activation of a patient's immune system offers an attractive approach to prevent and treat hepatocellular carcinoma (HCC). However, the antitumor efficacy of current HCC vaccines was weak owing to insufficient immune activation of targeting self/tumor antigens. We recently found that epitope-optimized α-fetoprotein ef...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.46

    authors: He Y,Hong Y,Mizejewski GJ

    更新日期:2014-01-01 00:00:00

  • Absence of CD4 T-cell help provides a robust CD8 T-cell response while inducing effective memory in a preclinical model of melanoma.

    abstract::Immunotherapy strategies for cancer are focused on inducing effective and specific cytotoxic responses mediated by CD8 T cells. On the other hand, immunosuppressive mechanisms induced by the tumor, such as the generation of tumor-specific CD4(+)CD25(+)FoxP3(+) Tregs, conspire against the efficacy of immunotherapies. I...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt.12.39

    authors: Muccioli M,Longstaff C,Benencia F

    更新日期:2012-05-01 00:00:00

  • Pseudoprogression of extramedullary disease in relapsed acute lymphoblastic leukemia after CAR T-cell therapy.

    abstract::Background: CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has emerged as a powerful immunotherapy in relapsed or refractory B-cell acute lymphoblastic leukemia. The changes in extramedullary (EM) disease in pediatric relapsed or refractory B-cell acute lymphoblastic leukemia after CAR T-cell therapy hav...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0188

    authors: Huang J,Rong L,Wang E,Fang Y

    更新日期:2021-01-01 00:00:00

  • Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.

    abstract::Epstein-Barr virus-associated lymphoproliferative diseases (EBV-LPD) after hematopoietic stem cell transplantation or solid-organ transplantation remain a serious and potentially life-threatening complication. In the last decade, outcomes for EBV-LPD have significantly improved. Key to this success was the development...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.10.43

    authors: Shaffer DR,Rooney CM,Gottschalk S

    更新日期:2010-09-01 00:00:00

  • Role of myeloid-derived suppressor cells in tumor immunotherapy.

    abstract::Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells that infiltrate human and experimental tumors and strongly inhibit anticancer immune response directly or by inducing regulatory T-lymphocyte activity. Consequently, MDSCs are important actors of cancer-induced immune tolerance and a major obstacle to...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.11.154

    authors: Martin F,Apetoh L,Ghiringhelli F

    更新日期:2012-01-01 00:00:00

  • Reslizumab for pediatric eosinophilic esophagitis.

    abstract::Pediatric eosinophilic esophagitis is an inflammatory condition associated with marked eosinophil accumulation in the mucosal tissues of the esophagus. Eosinophils are major proinflammatory cells thought to make a major contribution to allergic diseases that affect the upper and lower airways, skin and GI tract. IL-5 ...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt.10.41

    authors: Walsh GM

    更新日期:2010-07-01 00:00:00

  • Antibody-targeted nanoparticles for cancer therapy.

    abstract::In recent years, nanoparticulate-mediated drug delivery research has examined a full spectrum of nanoparticles that can be used in diagnostic and therapeutic cancer applications. A key aspect of this technology is in the potential to specifically target the nanoparticles to diseased cells using a range of molecules, i...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.11.5

    authors: Fay F,Scott CJ

    更新日期:2011-03-01 00:00:00

  • MAGE-A3: an immunogenic target used in clinical practice.

    abstract::Melanoma antigen family A, 3 (MAGE-A3) is a cancer-testis antigen whose expression has been demonstrated in a wide array of malignancies including melanoma, brain, breast, lung and ovarian cancer. In addition, its ability to elicit spontaneous humoral and cellular immune responses has been shown in cancer patients. As...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.15.29

    authors: Esfandiary A,Ghafouri-Fard S

    更新日期:2015-01-01 00:00:00

  • Immunotherapy of chronic myeloid leukemia: present state and future prospects.

    abstract::In spite of the considerable successes that have been achieved in the treatment of chronic myeloid leukemia (CML), cure for the disease can only be obtained by the present means in a rather small minority of patients. During the past decade, considerable progress has been made in the understanding of the immunology of...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.10.2

    authors: Vonka V

    更新日期:2010-03-01 00:00:00

  • Immunomodulatory effects of Lactobacillus strains: emphasis on their effects on cancer cells.

    abstract::Lactobacilli are a group of normal microbiota whose immunomodulatory effects have been known for a long time. Recently, they have gained more attention for their direct and indirect effects on cancer cells. Several cell line experiments, animal model studies as well as clinical trials have indicated their inhibitory e...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.15.92

    authors: Abedin-Do A,Taherian-Esfahani Z,Ghafouri-Fard S,Ghafouri-Fard S,Motevaseli E

    更新日期:2015-01-01 00:00:00

  • Immunotherapy for TB.

    abstract::Mycobacterium tuberculosis was one of the first human pathogens to be identified as the cause of a specific disease--TB. TB was also one of the first specific diseases for which immunotherapy was attempted. In more than a century since, multiple different immunotherapies have been attempted, alongside vaccination and ...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.12.52

    authors: Doherty TM

    更新日期:2012-06-01 00:00:00

  • Is faster safer? Cluster versus short conventional subcutaneous allergen immunotherapy.

    abstract:AIM:Few studies have compared cluster immunotherapy and conventional administration regimens. The aim of this study was to establish the safety profile of these different regimens in patients with allergic respiratory diseases who received index-of-reactivity (IR)-standardized allergen extracts by the subcutaneous rout...

    journal_title:Immunotherapy

    pub_type: 杂志文章,多中心研究

    doi:10.2217/imt.13.133

    authors: Quiralte J,Justicia JL,Cardona V,Dávila I,Moreno E,Ruiz B,García MA

    更新日期:2013-12-01 00:00:00

  • Adjuvant immunotherapies as a novel approach to bacterial infections.

    abstract::The rapid emergence of multidrug-resistant pathogens, especially Gram-negative bacteria and mycobacteria, represents one of the major medical challenges of the 21st century. The gradual loss of effective classical antibiotics for many bacterial pathogens, combined with an increasing population density and mobility, ur...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.13.17

    authors: Helbig ET,Opitz B,Sander LE

    更新日期:2013-04-01 00:00:00

  • Acute interstitial nephritis and PR3-ANCA following reintroduction of pembrolizumab: a case report.

    abstract::Renal toxicity from immune checkpoint inhibitors (ICIs) is an increasingly recognized cause of acute kidney injury among patients with cancer. ICI-associated acute kidney injuries typically present as acute interstitial nephritis and the timing of onset is highly variable. Herein, we present a case of a patient with r...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0223

    authors: Mulroy M,Ghafouri S,Sisk A,Ribas A,Goshtaseb R,Cherry G,Shen J

    更新日期:2021-03-01 00:00:00

  • Interview: Investigating immunomodulators among the Actinomycetales. Interview by Hannah Wilson.

    abstract::John L Stanford speaks to Hannah Wilson, Assistant Commissioning Editor John L Stanford is Chief Scientific Officer at BioEos Ltd (Kent, UK). Dr Stanford began his career as a senior lecturer and then reader in microbiology at Middlesex Hospital Medical School (London, UK), then University College London Medical Schoo...

    journal_title:Immunotherapy

    pub_type: 面试,新闻

    doi:10.2217/imt.13.27

    authors: Stanford JL

    更新日期:2013-05-01 00:00:00

  • Modulation of antitumor immunity with histone deacetylase inhibitors.

    abstract::Histone deacetylase inhibitors possess a broad array of antitumor activities; however, their net impact on the evolving antitumor immune response is highly dependent on the inhibitors used and the histone deacetylases they target. Herein, we sequentially focus on each stage of the antitumor immune response - from dend...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2017-0134

    authors: McCaw TR,Randall TD,Forero A,Buchsbaum DJ

    更新日期:2017-12-01 00:00:00